Literature DB >> 26503653

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

Adela Martin-Vicente1, Javier Capilla1, Josep Guarro2.   

Abstract

Aspergillus fumigatus is the main mold causing invasive fungal infection that shows high mortality rates. Therapeutic failure and the increase in drug resistance make it necessary to explore alternative treatments for this infection. We have evaluated the efficacy of amphotericin B at 0.8 mg/kg or 0.3 mg/kg of body weight combined with 40 mg/kg of posaconazole against three A. fumigatus isolates in a murine model of disseminated infection. The combination of the polyene and the azole led to a greater increase in survival and a significantly greater reduction in tissue burden than monotherapies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26503653      PMCID: PMC4704177          DOI: 10.1128/AAC.01462-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification.

Authors:  Michaela Lackner; Mohammad Javad Najafzadeh; Jiufeng Sun; Qiaoyun Lu; G Sybren de Hoog
Journal:  Appl Environ Microbiol       Date:  2011-11-04       Impact factor: 4.792

5.  Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.

Authors:  Issam I Raad; Aline El Zakhem; Gilbert El Helou; Ying Jiang; Dimitrios P Kontoyiannis; Ray Hachem
Journal:  Int J Antimicrob Agents       Date:  2014-10-12       Impact factor: 5.283

6.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Antonius J M M Rijs; Paul E Verweij; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

8.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.

Authors:  D Neofytos; D Horn; E Anaissie; W Steinbach; A Olyaei; J Fishman; M Pfaller; C Chang; K Webster; K Marr
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

9.  Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus.

Authors:  Eveline Snelders; Simone M T Camps; Anna Karawajczyk; Gijs Schaftenaar; Gert H J Kema; Henrich A van der Lee; Corné H Klaassen; Willem J G Melchers; Paul E Verweij
Journal:  PLoS One       Date:  2012-03-01       Impact factor: 3.240

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758

View more
  3 in total

1.  ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter.

Authors:  Ikuko Nakamura; Keisuke Ohsumi; Shinobu Takeda; Kiyomitsu Katsumata; Satoru Matsumoto; Souichiro Akamatsu; Hikaru Mitori; Toru Nakai
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 2.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

3.  Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis.

Authors:  Alba Pérez-Cantero; Dolores R Serrano; Patricia Navarro-Rodríguez; Andreas G Schätzlein; Ijeoma F Uchegbu; Juan J Torrado; Javier Capilla
Journal:  Pharmaceutics       Date:  2019-09-03       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.